Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Addition of Lenalidomide to Rituximab Maintenance Improves PFS in Elderly Patients With MCL

December 21st 2021

The addition of lenalidomide to rituximab maintenance treatment significantly improved progression-free survival compared with rituximab alone following first-line chemoimmunotherapy in patients with mantle cell lymphoma.

Parsaclisib Elicits Impressive Activity in Relapsed/Refractory MCL

December 20th 2021

The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.

Dr. McKinney on the Emergence of CAR T-Cell Therapy in Relapsed/Refractory MCL

December 14th 2021

Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Heyman on Future Therapeutic Directions in MCL

December 14th 2021

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Pirtobrutinib Overcomes Ibrutinib, Venetoclax Resistance in Heavily Pretreated MCL Cell Lines

December 12th 2021

The novel non-covalent BTK inhibitor pirtobrutinib showed promising preclinical efficacy in overcoming ibrutinib and venetoclax resistance, and in limiting cell growth and inducing apoptosis in mantle cell lymphoma.

Dr. McKinney on Emerging Therapeutic Strategies in MCL

December 10th 2021

Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses emerging therapeutic strategies in mantle cell lymphoma (MCL).

Dr. Heyman on ROR1-Targeted Approaches in Relapsed/Refractory MCL

December 9th 2021

Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Additional Efforts Needed to Optimize Treatment With BTK Inhibitors in MCL

October 29th 2021

Bijal Shah, MD, MS, discusses the evolving role of BTK inhibitors in MCL, how to choose among the variety of agents, and the safety concerns that affect treatment decisions.

Dr. McKinney on the Expanding Role of BTK Inhibitors in MCL

October 21st 2021

Matthew S. McKinney, MD, discusses the expanding role of BTK inhibitors in mantle cell lymphoma.

Novel Strategies With BTK Inhibitors Seek to Impact Frontline MCL Treatment Landscape

October 18th 2021

Brad S. Kahl, MD, discusses personalizing frontline treatment in mantle cell lymphoma, clinical trials further examining BTK inhibitors, and research opportunities with CAR T-cell therapy.

Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL

October 15th 2021

Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

Older Age Is Associated With Worse Survival Outcomes in MCL

October 15th 2021

Patients with newly diagnosed mantle cell lymphoma who were 65 years of age or older had worse progression-free survival and overall survival at 1 and 2 years compared with patients under the age of 65 years.

Dr. Erba on the Evolution of Treatment in MCL

October 14th 2021

Harry Paul Erba, MD, PhD, discusses the evolution of treatment in mantle cell lymphoma.

Autologous HSCT Shows Sustained Long-Term Benefit in MCL, But Role May Be Rechallenged By Novel Approaches

October 11th 2021

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma, confirming its place as the standard frontline treatment in this population.

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

September 23rd 2021

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Dr. Kahl on a Potential Limitation of Frontline BTK Inhibitor Combos in MCL

September 22nd 2021

Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.

Acalabrutinib Continues to Showcase Impressive Activity in Relapsed/Refractory MCL

September 21st 2021

Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.

Dr. Wang on the Significance of p53 Mutations in MCL

September 16th 2021

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL

September 15th 2021

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.